This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sirnaomics Ltd. Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases CI
Sirnaomics Finds No Serious Adverse Events During Phase 1 Study for Coagulation Drug MT
Sirnaomics Anticogulent Agent Successfully Completes 2nd Cohort of Phase I Clinical Study MT
Sirnaomics Ltd. Announces Interim Results for Successful Completion of the Second Cohort of Phase I Clinical Study of Galnac-Based Rnai Therapeutic Stp122g for Anticoagulant Therapeutics CI
Sirnaomics Ltd. Announces Changes in Composition of Board Committees CI
Sirnaomics Announces Completion Of STP707 Phase I Clinical Study Withstrong Safety Profile and Stable Disease Activityfor the Treatment of Pancreatic Cancer Patients CI
Sirnaomics Ltd. Announces Retirement of Directors and Change in Composition of Board Committees CI
Sirnaomics Medical, Finance Chiefs Step Down MT
Sirnaomics Ltd. Announces Resignation of Francois Lebel as the Chief Medical Officer CI
Sirnaomics Ltd. Announces Resignation of Yip Wing Kei as the Chief Financial Officer CI
Sirnaomics' Strategy Chief Steps Down MT
Sirnaomics Ltd. Announces Resignation of Dr. Xiaochang Dai as Chief Strategy Officer CI
Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director CI
Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment MT
Sirnaomics Ltd. Receives FDA Specific Guidance for Further Development of novel siRNA therapeutic, STP705 for Treatment of Squamous Cell Carcinoma in situ CI
Sirnaomics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sirnaomics Chairman Disposes of Shares MT
Sirnaomics Gets US FDA Nod for Clinical Trial of RSV Drug MT
Sirnaomics Concludes First Cohort of Phase 1 Anticoagulant Drug Study MT
Sirnaomics Ltd. Announces Successful Completion of Cohort 1 from Phase I Clinical Study of GalNAc-Based RNAi Therapeutic STP122G for Anticoagulant Treatment CI
Sirnaomics Ltd. Announces Executive Changes CI
Sirnaomics Shows Positive Effects of Focal Fat Reduction Drug at US Conference MT
Sirnaomics Ltd. Presents Positive Clinical Data of STP705 for Focal Fat Reduction CI
Sirnaomics Buys US Unit's Shares for $1 Million MT
Sirnaomics Completes Phase 1 Study Dosing of Cancer Medication MT
Chart Sirnaomics Ltd.
More charts
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6212 USD
Average target price
9.22 USD
Spread / Average Target
+1,384.29%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 2257 Stock
  4. News Sirnaomics Ltd.
  5. Sirnaomics Medical, Finance Chiefs Step Down